Alvogen is first with Revlimid rival in EU

Alvogen is claiming the first approvals in “several European countries” for its generic version of Celgene’s Revlimid (lenalidomide) capsules, after its Lotus Pharmaceuticals affiliate “successfully concluded multiple registration procedures” for the oncology drug. Lotus’ lenalidomide has been approved in European markets in seven strengths: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg capsules.

Alvogen is claiming the first approvals in “several European countries” for its generic version of Celgene’s Revlimid (lenalidomide) capsules, after its Lotus Pharmaceuticals affiliate “successfully concluded multiple registration procedures” for the oncology drug. Lotus’ lenalidomide has been approved in European markets in seven strengths: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg capsules.

Noting that Iceland acted as the reference member state (RMS) in the decentralised marketing-authorisation procedure, Lotus said its European application...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin